BCEL Atreca Inc

Price (delayed)

$1.895

Market cap

$73.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.9

Enterprise value

$90.83M

Atreca is a biopharmaceutical company developing novel antibody-based immunotherapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique ...

Highlights
Atreca's quick ratio has increased by 32% from the previous quarter but it has decreased by 19% YoY
Atreca's equity has decreased by 38% YoY and by 11% from the previous quarter
BCEL's net income is down by 18% YoY

Key stats

What are the main financial stats of BCEL
Market
Shares outstanding
38.59M
Market cap
$73.13M
Enterprise value
$90.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$108.42M
EBITDA
-$102.72M
Free cash flow
-$92.97M
Per share
EPS
-$2.9
Free cash flow per share
-$2.45
Book value per share
$3.65
Revenue per share
$0
TBVPS
$5.63
Balance sheet
Total assets
$213.69M
Total liabilities
$75.91M
Debt
$66.27M
Equity
$137.78M
Working capital
$110.14M
Liquidity
Debt to equity
0.48
Current ratio
9.57
Quick ratio
9.17
Net debt/EBITDA
-0.17
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-49.6%
Return on equity
-65%
Return on invested capital
-81.7%
Return on capital employed
-54%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BCEL stock price

How has the Atreca stock price performed over time
Intraday
-6.65%
1 week
11.47%
1 month
12.8%
1 year
-78.54%
YTD
-37.46%
QTD
-40.22%

Financial performance

How have Atreca's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.76M
Net income
-$108.43M
Gross margin
N/A
Net margin
N/A
BCEL's net income is down by 18% YoY
The operating income has contracted by 17% YoY

Growth

What is Atreca's growth rate over time

Valuation

What is Atreca stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Atreca's EPS has decreased by 8% YoY
The stock's price to book (P/B) is 49% less than its last 4 quarters average of 1.1
Atreca's equity has decreased by 38% YoY and by 11% from the previous quarter

Efficiency

How efficient is Atreca business performance
BCEL's ROE has shrunk by 56% YoY and by 11% QoQ
BCEL's return on assets is down by 32% year-on-year and by 4.6% since the previous quarter
The company's return on invested capital fell by 20% YoY but it rose by 13% QoQ

Dividends

What is BCEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BCEL.

Financial health

How did Atreca financials performed over time
BCEL's total assets is 182% more than its total liabilities
The total liabilities has surged by 88% year-on-year and by 68% since the previous quarter
Atreca's current ratio has increased by 32% QoQ but it has decreased by 20% YoY
BCEL's debt is 52% lower than its equity
Atreca's equity has decreased by 38% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.